Cardinal Health price target raised to $162 from $148 at Argus

Argus raised the firm’s price target on Cardinal Health (CAH) to $162 from $148 and keeps a Buy rating on the shares. The company is one of the U.S.’s largest distributors of pharmaceuticals and a global manufacturer and distributor of medical and laboratory products, and the firm has a favorable view of Cardinal’s long-term strategy and progress this past year amid an expanding health care market, despite expected volatility, the analyst tells investors in a research note.